Home / Health / Vision Loss Lawsuits Target Diabetes Drug Makers
Vision Loss Lawsuits Target Diabetes Drug Makers
22 Sep
Summary
- Hundreds are suing Novo Nordisk and Eli Lilly.
- Plaintiffs claim inadequate warnings about vision loss.
- Drugmakers deny allegations, assert patient safety.
Numerous lawsuits have been filed against major pharmaceutical companies Novo Nordisk and Eli Lilly. Hundreds of individuals are pursuing legal action, asserting that they were not sufficiently informed about the risks of vision loss associated with GLP-1 drugs. These plaintiffs contend that the manufacturers failed to adequately warn about potential dangers to eyesight.
In response, Novo Nordisk has stated that they are forcefully opposing the lawsuits, characterizing them as lacking any merit. Eli Lilly has also issued a statement, affirming that patient safety remains their paramount concern. The legal challenges highlight ongoing concerns regarding the disclosure of side effects for widely used GLP-1 medications.
